RetinalGenix Technologies IncOTCQB:RTGN
- LAST PRICE3.5000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 3.5000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RetinalGenix Technologies Inc | 62.2M | -29.1x | --- |
Maia Biotechnology Inc | 61.5M | -2.0x | --- |
OKYO Pharma Ltd | 49.6M | -0.1x | --- |
Mural Oncology PLC | 60.6M | -0.3x | --- |
Rallybio Corp | 64.3M | -0.9x | --- |
Lantern Pharma Inc | 59.1M | -3.7x | --- |
Company Information
RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.
Contact Information
- Headquarters
- 1450 North Mcdowell Boulevard, Suite 150PETALUMA, CA, United States 94954
- Phone
- 415-578-9583
- Fax
- 302-645-1280
Executives
- President, Chief Executive Officer, Director
- Jerry Katzman
- Interim Chief Financial Officer
- Virender Ahluwalia
- Director
- Dessislava Boneva
- Independent Director
- Herbert Gould
- Independent Director
- Vinay Mehindru
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.12 |
Book Value | $-0.08 |
P/E Ratio | -29.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
